Physiologically Based Pharmacokinetic Modeling to Evaluate Drug‐Drug Interactions of Tacrolimus With Ritonavir, a CYP3A Irreversible Inhibitor: Applications for Dosing Optimization in Transplant Patients
Clinical Pharmacology in Drug Development · 2025
DOI: 10.1002/cpdd.1572 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology in Drug Development, 2025. Verfasst von Yanjun Jiang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Phase I Clinical Trial Unit, The First Affiliated Hospital With Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: Ritonavir, Tacrolimus, Cytochrome P-450 CYP3A Inhibitors, Immunosuppressive Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 62 Literaturangaben.
Abstract (Originalsprache)
Immunosuppressant tacrolimus is frequently coadministered with other drugs in clinical practice. Ritonavir is a CYP3A irreversible inhibitor that is used in combination with nirmatrelvir for the treatment of COVID‐19 in nirmatrelvir/ritonavir. We aimed to apply physiologically based pharmacokinetic (PBPK) modeling to investigate the dose adjustment strategy for tacrolimus during short‐term coadministration with ritonavir. PBPK models for tacrolimus and ritonavir were successfully developed based on in vitro and clinical data, and were used to predict drug‐drug interaction levels via metabolic enzyme inhibition mechanisms. The recommended dose strategy based on our model simulation is to hold tacrolimus during nirmatrelvir/ritonavir treatment and restart half of the initial dose on day 3 after the 5‐day ritonavir course, followed by resuming the full dose on day 5. This administration strategy can maintain trough concentrations of tacrolimus within the therapeutic window during and after ritonavir treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Phase I Clinical Trial Unit, The First Affiliated Hospital With Nanjing Medical University, Nanjing, China.
- Department of Clinical Pharmacology, School of Pharmacy College, Nanjing Medical University, Nanjing, China.
- Animal Core Facility, Nanjing Medical University, Nanjing, China.
Zitieren
APA
Jiang, Y., Wang, L., Liu, J., Jiang, L., Li, K., Lv, Z., Zhou, S., & Shao, F. (2025). Physiologically Based Pharmacokinetic Modeling to Evaluate Drug‐Drug Interactions of Tacrolimus With Ritonavir, a CYP3A Irreversible Inhibitor: Applications for Dosing Optimization in Transplant Patients. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1572
Vancouver
Jiang Y, Wang L, Liu J, Jiang L, Li K, Lv Z, et al. Physiologically Based Pharmacokinetic Modeling to Evaluate Drug‐Drug Interactions of Tacrolimus With Ritonavir, a CYP3A Irreversible Inhibitor: Applications for Dosing Optimization in Transplant Patients. Clinical Pharmacology in Drug Development. 2025. doi:10.1002/cpdd.1572
BibTeX
@article{Jiang2025,
author = {Jiang, Yanjun and Wang, Lu and Liu, Jia and Jiang, Lizhen and Li, Kang and Lv, Zhanhui and Zhou, Sufeng and Shao, Feng},
title = {Physiologically Based Pharmacokinetic Modeling to Evaluate Drug‐Drug Interactions of Tacrolimus With Ritonavir, a CYP3A Irreversible Inhibitor: Applications for Dosing Optimization in Transplant Patients},
journal = {Clinical Pharmacology in Drug Development},
year = {2025},
doi = {10.1002/cpdd.1572}
}
EUVIMED